PYXS stock icon

Pyxis Oncology
PYXS

$3.37
0.27%
 

About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Employees: 51

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 7 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

517% more capital invested

Capital invested by funds: $15.8M [Q4 2023] → $97.7M (+$81.8M) [Q1 2024]

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

190% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 10

167% more call options, than puts

Call options by funds: $543K | Put options by funds: $203K

37% more funds holding

Funds holding: 51 [Q4 2023] → 70 (+19) [Q1 2024]

19.6% more ownership

Funds ownership: 19.85% [Q4 2023] → 39.44% (+19.6%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
108%
upside
Avg. target
$8.29
146%
upside
High target
$12
256%
upside

7 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
108%upside
$7
Buy
Reiterated
16 May 2024
Jefferies
Farzin Haque
197%upside
$10
Buy
Assumed
7 May 2024
HC Wainwright & Co.
Swayampakula Ramakanth
108%upside
$7
Buy
Reiterated
10 Apr 2024
RBC Capital
Leonid Timashev
108%upside
$7
Outperform
Reiterated
22 Mar 2024
HC Wainwright & Co.
Swayampakula Ramakanth
108%upside
$7
Buy
Maintained
22 Mar 2024

Financial journalist opinion